Doryx Shortage: What Providers and Prescribers Need to Know in 2026

Patients are increasingly contacting your office because they cannot find Doryx MPC at their pharmacy. Understanding the current supply landscape, dosing equivalencies between formulations, and appropriate clinical alternatives will help you guide patients efficiently and avoid delays in treatment.

Current Availability Status (2026)

Doryx MPC (doxycycline hyclate delayed-release tablets with modified polymer coating), manufactured by Mayne Pharma, does not have an active FDA-declared national shortage as of 2026. However, several factors contribute to patients' difficulty accessing it:

The original Doryx formulation was discontinued; many pharmacies have not fully updated their systems to carry Doryx MPC as the successor product.

Doryx MPC's high retail cost ($700–$1,600+ without insurance) discourages routine pharmacy stocking.

An authorized generic was approved but has had limited commercial availability as of 2026.

Residual spot shortages of generic doxycycline hyclate occur regionally; the 2023–2024 national shortage largely resolved, but supply fragility persists.

Critical Prescribing Note: Doryx MPC Is Not mg-for-mg Substitutable

This is the most clinically important point for prescribers: Doryx MPC cannot be substituted milligram-for-milligram with other oral doxycycline formulations. The modified polymer coating results in different bioavailability:

Doryx MPC 120 mg ≈ standard doxycycline hyclate 100 mg (bioequivalent per FDA data)

Doryx MPC 60 mg ≈ standard doxycycline 50 mg

When transitioning a patient from Doryx MPC to standard doxycycline (or vice versa), the prescription must be rewritten with the adjusted dose. Pharmacy-level substitution is not appropriate here.

Clinical Alternatives by Indication

If Doryx MPC is unavailable or unaffordable, the following alternatives are appropriate depending on the indication:

Acne Vulgaris

Generic doxycycline hyclate: 100 mg once or twice daily (adjust dose from Doryx MPC; not a direct mg-for-mg substitution). Widely available and very affordable.

Minocycline (generic): 50–100 mg twice daily or extended-release 1 mg/kg/day. Comparable efficacy to doxycycline for acne; notable differences include higher sebaceous penetration but greater risk of autoimmune reactions and permanent pigmentation changes.

Sarecycline (Seysara): Narrow-spectrum third-generation tetracycline FDA-approved for moderate-to-severe inflammatory acne in patients ≥9 years. Dosing is weight-based (60–150 mg once daily). Lower antibiotic resistance concern than broad-spectrum agents.

Sexually Transmitted Infections

Chlamydia: Azithromycin 1 g single oral dose is the primary CDC-recommended alternative when doxycycline is unavailable.

NGU (non-gonococcal urethritis): Azithromycin 1 g single dose or levofloxacin 500 mg for 7 days.

Tick-Borne and Rickettsial Diseases

For Rocky Mountain spotted fever and rickettsial diseases, doxycycline remains the preferred treatment. The CDC and AAP have noted that no alternative can be recommended with the same proven degree of efficacy for limiting fatal outcomes. If Doryx MPC specifically is unavailable, prescribe generic doxycycline hyclate 100 mg twice daily and ensure patients can find it. If there is difficulty obtaining any doxycycline formulation, contact your state health department.

Lyme Disease

Amoxicillin 500 mg three times daily for 14–21 days (preferred for pregnant patients and children under 8)

Cefuroxime 500 mg twice daily for 14–21 days

Helping Patients Access Doryx MPC

When Doryx MPC is the preferred treatment and you want to help patients access it, medfinder for providers helps identify pharmacies in your patients' areas that carry Doryx MPC and can fill their prescriptions. This reduces callbacks from patients and pharmacy staff.

Additionally, the Mayne Pharma patient savings program and GoodRx can reduce out-of-pocket costs for Doryx MPC to as low as $25/month — which may resolve a cost barrier for uninsured or underinsured patients.

Documentation and Prescribing Best Practices

When prescribing Doryx MPC, specify the brand name and 'modified polymer coating' to ensure pharmacists look for the correct product, not the discontinued original Doryx.

If switching a patient from Doryx MPC to generic doxycycline, document the dose adjustment rationale in the chart (Doryx MPC 120 mg → doxycycline hyclate 100 mg).

If prescribing for acne, consider pairing any oral antibiotic with a topical benzoyl peroxide or retinoid to reduce resistance selection pressure per AAD guidelines.

Key Takeaways for Providers

Doryx MPC is available from Mayne Pharma, but inconsistently stocked at many pharmacies — this is a distribution issue, not a manufacturing crisis.

Doryx MPC is NOT substitutable mg-for-mg with other doxycyclines; dose adjustment is required when switching.

For acne, minocycline and sarecycline are reasonable alternatives. For infections, alternatives vary by pathogen.

medfinder can help patients locate pharmacies with Doryx MPC in stock, reducing callbacks and delays. Learn more at medfinder.com/providers.